Vertex Pharma (VRTX) stock slips as UnitedHealth (UNH) offers its pain drug Journavx Tier 3 coverage, setting a rivalry with ...

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Editas Medicine (EDIT – Research Report) yesterday and set a price target of ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

On track to declare two in vivo editingdevelopment candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...